M0 CRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans
(Length of Conversation: 24 min)
Alicia Morgans and Charles Ryan discuss data that was presented at the ASCO GU 2018 meeting including two phase III trials, Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) and the advances for nonmetastatic castration-resistant prostate cancer (nmCRPC). They overview the two trials, the importance of treating nmCRPC and the outcomes in the use of new androgen receptor targeted therapies.
Other topics discussed include patient selection, the development of metastasis, the role of imaging in the context of the studies and the biology of the disease, next treatments in regards to M1 CRPC and the second progression data, and the importance of aggressively continuing to understand the patterns of resistance.
Charles J. Ryan, MD
Alicia Morgans, MD, MPH
Further Related Content:
Watch: First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Watch: First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
Watch: The Incredible Shrinking M0 CRPC - Phillip Koo
From the Desk of the Editor: "Targeting the Unseen: Advances in Treatment of M0 CRPC"
Non-metastatic CRPC: The Five Essentials - Charles Ryan